• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Research Brief on 1-(1-Cyclopropylethyl)-1H-pyrazol-4-amine (CAS: 1251266-33-7): Recent Advances and Applications

The compound 1-(1-Cyclopropylethyl)-1H-pyrazol-4-amine (CAS: 1251266-33-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This pyrazole derivative has shown promising potential as a key intermediate or active moiety in the development of novel therapeutic agents. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, particularly in the context of kinase inhibition and targeted drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 1-(1-Cyclopropylethyl)-1H-pyrazol-4-amine as a scaffold for designing selective kinase inhibitors. The research team demonstrated that modifications to the cyclopropyl group and the amine functionality could significantly alter the compound's binding affinity to specific kinase targets, particularly those involved in inflammatory pathways. The study reported a 4.2-fold increase in potency compared to earlier analogs when tested against JAK3 kinases.

In the area of synthetic methodology, a recent breakthrough published in Organic Letters (2024) described an efficient three-step synthesis of 1251266-33-7 with improved yield (78%) and purity (>99%). The new protocol utilizes a copper-catalyzed cyclopropanation followed by a regioselective amination, addressing previous challenges in the large-scale production of this compound. This advancement is particularly relevant for pharmaceutical companies considering this molecule for clinical development.

Biological evaluations have revealed interesting properties of 1-(1-Cyclopropylethyl)-1H-pyrazol-4-amine derivatives. A preclinical study demonstrated that certain analogs exhibit dual activity as both kinase inhibitors and allosteric modulators of G-protein-coupled receptors (GPCRs). This unique pharmacological profile suggests potential applications in treating complex diseases where multiple pathways are dysregulated, such as autoimmune disorders and certain cancers.

The compound's physicochemical properties have also been thoroughly characterized in recent computational studies. Molecular dynamics simulations indicate that the cyclopropyl group confers significant conformational rigidity to the molecule, while the pyrazole-amine moiety provides optimal hydrogen bonding capacity for target engagement. These features make 1251266-33-7 an attractive scaffold for fragment-based drug discovery approaches.

Several pharmaceutical companies have included derivatives of 1-(1-Cyclopropylethyl)-1H-pyrazol-4-amine in their development pipelines. Patent filings from 2023-2024 reveal applications in oncology (particularly for hematological malignancies), inflammatory diseases, and neurological disorders. The compound's favorable ADME (absorption, distribution, metabolism, and excretion) profile, as evidenced by recent pharmacokinetic studies, enhances its translational potential.

Looking forward, researchers are exploring the use of 1251266-33-7 in PROTAC (proteolysis targeting chimera) development, where its binding properties could be leveraged to target specific proteins for degradation. Early results suggest that the compound's structure allows for effective linker attachment without compromising target engagement, opening new avenues for targeted protein degradation therapies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)